Posted by | Posted in Cancer & Health News | Posted on 22-02-2010
HealthDay – THURSDAY, Feb. 18 (HealthDay News) — The U.S. Food and Drug
Administration is defending its decision in late January to approve a new
diabetes drug, Victoza (liraglutide), even though animal studies suggest
it might increase the risk for a rare thyroid cancer.
